Mode
Text Size
Log in / Sign up
N/A N=57

SB3 Battery Life Observational Study

Capsule Endoscopy

Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Apr 2019
Primary outcome: Primary: Completion Rate (Rate at Which Small Bowel is Completely Examined) — 57 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Adult, Older Adult · 19+ yrs
Sex
All
Sponsor
University of British Columbia
Primary completion
Dec 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Completion Rate (Rate at Which Small Bowel is Completely Examined)
57
SECONDARY
Diagnostic Yield
20
SECONDARY
Gastric Transit Time
37.6
SECONDARY
Small Bowel Transit Time
232.1

Summary

Capsule endoscopy (CE) is a non-invasive means of visualizing the small bowel. Common indications for CE include obscure gastrointestinal (GI) bleeding, inflammatory bowel disease like crohn's disease or ulcerative colitis, celiac disease, and polyposis syndrome. While CE has high diagnostic value for small bowel lesions, a significant limitation of this technology is the finite battery life which results in incomplete examination of the small bowel approximately 16.5% of the time. Numerous attempts of using pharmacological (e.g. prokinetics, purgatives) as well as non-pharmacological measures (e.g. real-time viewer, chewing gum) to improve completion rates, defined by entry of CE into the cecum, led to mixed results. Currently routine use of prokinetics (agents that speeds up gut motility) is not recommended. This study aims to determine whether longer battery of the newer generation capsule endoscopy system improves study completion rate and diagnostic yield.

Eligibility Criteria

Inclusion Criteria

  • Male or female age 19 or greater who are referred for small bowel capsule endoscopy
  • Willing and able to provide written informed consent

Exclusion Criteria

  • Unwillingness or inability to swallow pill
  • Known or suspected obstruction or bowel stricture
  • Endoscopic placement of capsule camera
  • Concomitant enrollment in a prospective study in the treatment arm receiving prokinetics for the purpose of enhancing bowel motility. (i.e. control arm not receiving any motility-enhancing agent can be included)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02382705). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search